| Basics |
Amicus Therapeutics, Inc.
Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines.
|
| IPO Date: |
May 31, 2007 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.05B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.65%
|
| Avg Daily Range (30 D): |
$0.14 | 1.45%
|
| Avg Daily Range (90 D): |
$0.14 | 1.75%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.54M |
| Avg Daily Volume (30 D): |
4.06M |
| Avg Daily Volume (90 D): |
4.05M |
| Trade Size |
| Avg Trade Size (Sh.): |
147 |
| Avg Trade Size (Sh.) (30 D): |
137 |
| Avg Trade Size (Sh.) (90 D): |
150 |
| Institutional Trades |
| Total Inst.Trades: |
7,586 |
| Avg Inst. Trade: |
$2.9M |
| Avg Inst. Trade (30 D): |
$2.97M |
| Avg Inst. Trade (90 D): |
$2.86M |
| Avg Inst. Trade Volume: |
.26M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.64M |
| Avg Closing Trade (30 D): |
$5.6M |
| Avg Closing Trade (90 D): |
$5.3M |
| Avg Closing Volume: |
332.51K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.06
|
$-.08
|
|
Diluted EPS
|
|
$.06
|
$-.08
|
|
Revenue
|
$
|
$ 169.06M
|
$ 154.69M
|
|
Gross Profit
|
$
|
$ 149.59M
|
$ 139.47M
|
|
Net Income / Loss
|
$
|
$ 17.31M
|
$ -24.42M
|
|
Operating Income / Loss
|
$
|
$ 34.27M
|
$ -9.47M
|
|
Cost of Revenue
|
$
|
$ 19.47M
|
$ 15.22M
|
|
Net Cash Flow
|
$
|
$ 31.84M
|
$ -22.72M
|
|
PE Ratio
|
|
|
|
|
|
|
